Pfenex Announces U.S. Commercial Launch of Teriparatide Injection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
Pfenex Inc. (PFNX) PT Raised to $15 at Oppenheimer
June 15, 2020 9:19 AM EDTOppenheimer analyst Francois Brisebois raised the price target on Pfenex Inc. (NYSE: PFNX) to $15.00 (from $10.00) while maintaining a Outperform rating following the company's announcement that its commercial partner Alvogen opted to proceed with the US launch of PF708 to increase bone density in... More
